Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HALT-MS
NCT00288626Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2006
- Primary completion
- Nov 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD34+ hematopoietic stem cells in relapsing-remitting multiple sclerosis (RRMS), sponsored by National Institute of Allergy and Infectious Diseases. Started Jul 2006; status: completed.
02
Drugs
autologous CD34+ hematopoietic stem cells
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00288626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288626.